My watch list  


Systematic (IUPAC) name
CAS number  ?
ATC code C01DX19
PubChem  ?
Chemical data
Formula C143H244N50O42S4 
Mol. mass 3464 g/mol
Pharmacokinetic data
Bioavailability  ?
Metabolism  ?
Half life  ?
Excretion  ?
Therapeutic considerations
Pregnancy cat.


Legal status
Routes IV only

Nesiritide (Natrecor®) is a medication used to treat acutely decompensated congestive heart failure with dyspnea at rest or with minimal exertion (such as talk, eating or bathing). Nesiritide is the recombinant form of the 32 amino acid human B-type natriuretic peptide, which is normally produced by the ventricular myocardium. Nesiritide works to facilitate cardiovascular fluid homeostasis through counterregulation of the renin-angiotensin-aldoesterone system, stimulating cyclic guanosine monophosphate, leading to smooth muscle cell relaxation. In simpler terms, it promotes vasodilation, natriuresis, and diuresis.



Nesiritide is only administered intravenously, usually by bolus, followed by IV infusion. For most adults and the elderly, a normal dosage is 2 micrograms/kilogram followed by a continuous IV infusion of 0.01 mcg/kg/minute. This may be increased every three hours for a maximum of 0.03 mg/kg/min.

Correction - maximum dose is 0.03 MCG/kg/minute, not MG.

Side effects

Common side effects include:

  • Low blood pressure (11% of patients)
  • Headache
  • Nausea
  • Slow heart rate

More rare side effects include:

  • Confusion
  • Paresthesia
  • Somnolence
  • Tremors

Recommendations for use (as of 7/13/2005)

There have been several meta-analysis which have identified issues of increased mortality and increased renal dysfunction with use of nesiritide compared to usual therapy. As a result, the company which manufactures nesiritide (Scios), consulted with Dr E Braunwald to develop recommendations for use.[1] They are as follows:

  • The use of nesiritide should be strictly limited to patients presenting to the hospital with acutely decompensated heart failure who have dyspnea at rest, as were the patients in the largest trial that led to approval of the drug (VMAC). Physicians considering the use of nesiritide should consider its efficacy in reducing dyspnea, the possible risks of the drug (refers to meta-analysis), and the availability of alternate therapies to relieve the symptoms of congestive heart failure.
  • Nesiritide should not be used to replace diuretics. Furthermore, because insufficient evidence is not currently available to demonstrate benefit for the applications listed below,
    • for intermittent outpatient infusion
    • for scheduled repetitive use
    • to improve renal function
    • to enhance diuresis


  1. ^


  • Hodgson, Barbara B., and Kizior, Robert J. Saunders Nursing Drug Handbook 2006. St. Louis, MO: Elsevier, Saunders, 2006.
  • Science or Fiction: Use of Nesiritide as a First-Line Agent? John A. Noviasky, Pharm.D., Michael Kelberman, M.D., Karen M. Whalen, B.S., Roy Guharoy, Pharm.D., William Darko, Pharm.D.[1]

This article is licensed under the GNU Free Documentation License. It uses material from the Wikipedia article "Nesiritide". A list of authors is available in Wikipedia.
Your browser is not current. Microsoft Internet Explorer 6.0 does not support some functions on Chemie.DE